Literature DB >> 22491617

Prediction of clinical outcomes for massively-burned patients via serum transthyretin levels in the early postburn period.

Hyeong Tae Yang1, Haejun Yim, Yong Suk Cho, Dohern Kim, Jun Hur, Jong Hyun Kim, Boung Chul Lee, Dong Kook Seo, Hyun Soo Kim, Wook Chun.   

Abstract

BACKGROUND: We observed that serum transthyretin (TTR) levels consistently remain low when patients' general conditions are poor, despite adequate nutritional support. We conducted this study to analyze the changes of serum TTR over time from injury in massively-burned patients and verify the validity of prediction by clinical outcomes, which are assessed via serum TTR in the early postburn period.
METHODS: From January 2005 to December 2010, the samples of serum TTR from 471 burn patients (mean % total body surface area [TBSA] burned, 51% ± 20%) were analyzed with time frames from injury retrospectively.
RESULTS: Serum TTR significantly decreased during the period from day 5 to day 10 postinjury in both the survival group (n = 290, mean %TBSA burned, 42.9% ± 14.2%) and nonsurvival group (n = 181, mean %TBSA burned, 64.6% ± 20.8%). However, after this period, the serum TTR constantly increased in the survival group but remained low in nonsurvivors. At all time, the levels of serum TTR obtained from survivors were significantly higher than those of nonsurvivors. The serum TTR had weak correlation with the extent of the burn injury (r = -0.234). Survival rates of the patients increased significantly by the increase of the serum TTR of early postburn period. In multivariable model, age (odds ratio [OR], 1.054; 95% confidence interval [CI], 1.043-1.066; p = 0.000), TBSA burned (OR, 1.058; 95% CI, 1.051-1.066; p = 0.000), sex (OR, 0.720; 95% CI, 0.547-0.947; p = 0.019), and serum TTR during early postburn period (OR, 1.05; 95% CI, 0.873-0.972; p = 0.003) were independently associated with mortality.
CONCLUSIONS: The serum TTR of early postburn period can be used as a prognostic markers, and low serum TTR can be used as a signal for screening out the patients at risk who need careful assessment and monitoring at an early stage.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22491617     DOI: 10.1097/TA.0b013e3182413bd8

Source DB:  PubMed          Journal:  J Trauma Acute Care Surg        ISSN: 2163-0755            Impact factor:   3.313


  2 in total

1.  Transthyretin at Admission and Over Time as a Marker for Clinical Outcomes in Critically Ill Trauma Patients: A Prospective Single-Center Study.

Authors:  Tobias Haltmeier; Kenji Inaba; Joseph Durso; Moazzam Khan; Stefano Siboni; Vincent Cheng; Beat Schnüriger; Elizabeth Benjamin; Demetrios Demetriades
Journal:  World J Surg       Date:  2020-01       Impact factor: 3.352

Review 2.  Plasma transthyretin is a nutritional biomarker in human morbidities.

Authors:  Yves Ingenbleek
Journal:  Front Med       Date:  2022-08-09       Impact factor: 9.927

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.